#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Squamous cell carcinoma of the hypopharynx Pulmonary fibrosis Vascular calcification Precursor T-lymphoblastic lymphoma/leukaemia recurrent Epidermolysis bullosa Plasma cell myeloma recurrent Cervix carcinoma Hereditary hypophosphataemic rickets Stiff person syndrome Deafness Desmoplastic small round cell tumour Rheumatoid arthritis Kawasaki's disease Thermal burn Rett syndrome More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Basic Information Glomerulonephritis membranoproliferative – Treatment Hereditary optic atrophy Hereditary ataxia Breast angiosarcoma – Trials in Disease Propionic acidaemia Immunodeficiency congenital Mast cell activation syndrome – Diagnostics Synovial sarcoma Ewing’s sarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    18F-Psma-1007 Lasmiditan Seladelpar Clomifene Citrate Ds-3939A Apocynin Finasteride Protein S VTX-002 Metoclopramide Gindameran Rp1 F44/10 HUMAN COAGULATION FACTOR XIII Cellulose, Microcrystalline Elritercept Posaconazole Bulevirtide Progesterone Tebentafusp More therapies…

    Learn about Your Condition

    Malformation venous Immune thrombocytopenia Arrhythmia supraventricular Acute cardiac event Hypochondroplasia Portal hypertension Tympanic membrane hyperaemia Craniopharyngioma Sickle cell disease Neurogenic bladder Juvenile idiopathic arthritis Bladder cancer recurrent Mitochondrial myopathy Pterygium Cryoglobulinaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. CHU Croix Rousse-Lyon

CHU Croix Rousse-Lyon

103 Grande Rue De La Croix Rousse, Lyon, 69317, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium France Germany Italy Spain

  • Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung disorder
    Investigated Drugs:
    • Baricitinib
    Austria Belgium Czechia France Germany Greece +8

  • Study on Asthma Control and Adherence with Mepolizumab in Pre-filled Devices for Patients with Asthma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Beclometasone Dipropionate Anhydrous
    • Fluticasone Furoate
    • Glycopyrronium Bromide
    France

  • Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Hepatic cancer
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Ipilimumab
    France

  • Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatitis D
    Investigated Drugs:
    • Bulevirtide
    Austria Belgium France Germany The Netherlands Romania +1

  • Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Czechia France Poland Romania Spain

  • Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma

    Not recruiting

    3 1
    Investigated Drugs:
    • Citicoline Sodium
    Belgium France Greece Hungary Italy Poland +1

  • Study on BJT-778 for Patients with Chronic Hepatitis B and D Infections

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Chronic hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Bjt-778
    • Sodium Chloride
    Bulgaria France Romania

  • Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    Denmark France Germany Hungary Ireland Italy +3

  • Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Rifaximin
    Belgium Bulgaria France Germany Hungary Italy +2
Previous Page
1 … 9 10 11 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!